Madrigal Pharmaceuticals Inc (MDGL) USD0.00010

Sell:$323.99Buy:$324.61$3.83 (1.16%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$323.99
Buy:$324.61
Change:$3.83 (1.16%)
Market closed | Prices delayed by at least 15 minutes
Sell:$323.99
Buy:$324.61
Change:$3.83 (1.16%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Key people

Bill Sibold
President, Chief Executive Officer, Director
Mardi C. Dier
Chief Financial Officer, Senior Vice President
Rebecca A. Taub
President of Research and Development, Chief Medical Officer, Director
Michael R. Charlton
Senior Vice President - Clinical Development
Shannon Kelley
General Counsel
Carole A Huntsman
Chief Commercial Officer
Robert Waltermire
Chief Pharmaceutical Development Officer
Julian C. Baker
Independent Chairman of the Board
Frederick B. Craves
Lead Independent Director
Jacqualyn Fouse
Director
Paul A. Friedman
Director
Kenneth M. Bate
Independent Director
Click to see more

Key facts

  • EPIC
    MDGL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US5588681057
  • Market cap
    $7.31bn
  • Employees
    528
  • Shares in issue
    22.08m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.